Volume 5 Supplement 3
Novel B-lymphocyte-deleting agents for the treatment of autoimmune diseases: induction of the mitochondrial pathway of apoptosis
© The Author(s) 2003
Published: 12 September 2003
To develop new approaches for the targeted deletion of pathogenic autoimmune B lymphocytes, we have studied a bacterial product, protein A of Staphylococcus aureus (SpA). We have previously discovered that SpA has the properties of a B-cell superantigen, enabling interactions with conserved variable region framework subdomains of the antigen receptors of lymphocytes rather than the complementarity determining region involved in the binding of conventional antigens . Exposure to SpA can induce immune tolerance affecting a supraclonal set of lymphocytes .
To evaluate the outcome of in vivo SpA treatment.
Within hours, a sequence of events is initiated only in targeted B cells, with rapid downregulation of B-cell antigen receptor and the coreceptors CD19 and CD21, the induction of an activation phenotype, and limited rounds of proliferation. Massive B-cell-specific apoptosis then occurs through a process heralded by the dissipation of mitochondrial membrane potential, followed later by the induction of the caspase pathway and DNA fragmentation. Post exposure, B-cell apoptotic bodies are deposited in the spleen, the lymph nodes and Peyers patches. While in vivo apoptosis does not require a death receptor, such as Fas, recent studies have demonstrated that apoptosis is linked to an induced imbalance in the members of the Bcl-2 family. By microfluorimetry and deconvoluted confocal microscopy, SpA induced a rapid depletion of Bcl-XL. There was also increased expression and translocation of a pro-apoptotic BH3-only member, which can form heterodimers resulting in Bax/Bak-mediated death.